Contemporary OB/GYN editorial board member Ilana Cass, MD, offers perspective on the recent FDA approval of the first-ever alternative to Pap smear cytology cervical screening.
Contemporary OB/GYN editorial board member Ilana Cass, MD, offers perspective on the recent FDA approval of the first-ever alternative to Pap smear cytology cervical screening.
"The Food and Drug Administration has approved the cobas HPV test as first-line testing for cervical cancer screening in women ages 25 and older. The significance of this approval is that HPV testing would be the first-ever alternative to Pap smear cytology cervical screening. The endorsement was based upon results from the ATHENA study, which showed that HPV testing was more sensitive in identifying cervical intraepithelial neoplasia-3 (CIN-3) when compared to liquid-based Pap smear cytology. The ATHENA trial is the largest HPV screening trial in the United States with almost 41, 000 women aged 25 or older, although final results of the ATHENA trial have not yet been published. The FDA approval of primary HPV testing means that primary HPV testing is considered a safe and effective option to screen women for cervical cancer, but the FDA approval does not issue guidelines about the use of a test or change current screening recommendations. Organizations such as SGO, ACOG and the ASCCP are currently working to develop interim guidelines to determine how primary HPV testing will be incorporated into cervical cancer screening."
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More